Omega-3 fatty acids and hypertriglyceridemia in HIV-infected subjects on antiretroviral therapy: Systematic review and meta-analysis

HIV Clinical Trials

Volumn 12, Issue 5, 2011, Pages 268-274

  Oliveira, Julicristie ^a   Rondó, Patrícia ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

AIDS; HIV; omega 3 fatty acids; triglycerides

Indexed keywords

ANTIRETROVIRUS AGENT; FISH OIL; OMEGA 3 FATTY ACID ESTER; PLACEBO; TRIACYLGLYCEROL;

ARTICLE; DIET THERAPY; DRUG EFFECT; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTRIGLYCERIDEMIA; META ANALYSIS; MULTICENTER STUDY (TOPIC); PATIENT COUNSELING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; TRIACYLGLYCEROL BLOOD LEVEL;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DOUBLE-BLIND METHOD; FATTY ACIDS, OMEGA-3; HIV INFECTIONS; HUMANS; HYPERTRIGLYCERIDEMIA; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME; TRIGLYCERIDES;

EID: 84255184777     PISSN: 15284336     EISSN: 19455771     Source Type: Journal    
DOI: 10.1310/hct1205-268     Document Type: Article

References (27)

1. Barbaro G. Highly active antiretroviral therapy-associated metabolic syndrome: pathogenesis and cardiovascular risk. Am J Ther. 2006;13:248-260. (Pubitemid 44026193)
2. Barbaro G, Barbarini G. Highly active antiretroviral therapy-associated metabolic syndrome and cardiovascular risk. Chemotherapy. 2006;52:161-165. (Pubitemid 43882412)
3. Oh J, Hegele RA. HIV-associated dyslipidaemia: pathogenesis and treatment. Lancet Infect Dis. 2007;7:787-796. (Pubitemid 350153668)
4. Friis-Møller N, Weber R, Reiss P, et al. Cardiovascular disease risk factors in HIV patients association with antiretroviral therapy. Results from the DAD study. AIDS. 2003;17:1179-1193. (Pubitemid 36667761)
5. Thusgaard M, Christensen JH, Mørn B, et al. Effect of fi sh oil (n-3 polyunsaturated fatty acids) on plasma lipids, lipoproteins and inflammatory markers in HIV-infected patients treated with antiretroviral therapy: a randomized, double-blind, placebo-controlled study. Scand J Infect Dis. 2009;41:760-766.
6. Baril JG, Kovacs CM, Trottier S, et al. Effectiveness and tolerability of oral administration of low-dose salmon oil to HIV patients with HAART-associated dyslipidemia. HIV Clin Trials. 2007;8:400-411. (Pubitemid 350305214)
7. De Truchis P, Kirstetter M, Perier A, et al. Reduction in triglyceride level with N-3 polyunsaturated fatty acids in HIV-infected patients taking potent antiretroviral therapy: a randomized prospective study. J Acquir Immune Defic Syndr. 2007;44:278-285. (Pubitemid 46328343)
8. Wohl DA, Tien HC, Busby M, et al. Randomized study of the safety and Efficacy of fi sh oil (omega-3 fatty acid) supplementation with dietary and exercise counselling for the treatment of antiretroviral therapy-associated hypertriglyceridemia. Clin Infect Dis. 2005;41:1498-1450.
9. Carter VM, Woolley I, Jolley D, Nyulasi I, Mijch A, Dart A. A randomised controlled trial of omega-3 fatty acid supplementation for the treatment of hypertriglyceridemia in HIV-infected males on highly active antiretroviral therapy. Sex Health. 2006;3:287-290.
10. Manfredi R, Calza L, Chiodo F. Polyunsaturated ethyl esters of n-3 fatty acids in HIV-infected patients with moderate hypertriglyceridemia: comparison with dietary and lifestyle changes, and fi brate therapy. J Acquir Immune Defic Syndr. 2004;36: 878-880. (Pubitemid 38859356)
11. McKenney JM, Sica D. Role of prescription omega-3 fatty acids in treatment of hypertriglyceridemia. Pharmacotherapy. 2007;27:715-728. (Pubitemid 46700964)
12. Downs SH, Black N. The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. J Epidemiol Community Health. 1998:52:377-384. (Pubitemid 28438523)
13. Harris WS. N-3 fatty acids and serum lipoproteins: human studies. Am J Clin Nutr. 1997;65:1645S-1654S. (Pubitemid 27187958)
14. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) fi nal report. Circulation. 2002;106:3143-3421.
15. Jacobson TA. Role of n-3 fatty acids in the treatment of hypertriglyceridaemia and cardiovascular disease. Am J Clin Nutr. 2008;87:1981-1990
16. Kim SH, Kim MK, Lee HY, Kang HJ, Kim YJ, Kim HS. Prospective randomized comparison between omega-3 fatty acid supplements plus simvastatin versus simvastatin alone in Korean patients with mixed dyslipidemia: lipoprotein profi les and heart rate variability. Eur J Clin Nutr. 2011;65:110-116.
17. Davidson MH, Stein EA, Bays HE, et al; COMBination of prescription Omega-3 with Simvastatin (COMBOS) Investigators. Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study. Clin Ther. 2007;29:1354-1367. (Pubitemid 47348116)
18. Gerber JG, Kitch DW, Fichtenbaum CJ, et al. Fish oil and fenofi brate for the treatment of hypertriglyceridemia in HIVinfected subjects on antiretroviral therapy: results of ACTG A5186. J Acquir Immune Defic Syndr. 2008;47:459-466. (Pubitemid 351366958)
19. Eslick GD. Benefi ts of fi sh oil supplementation in hyperlipidemia: a systematic review and meta-analysis. Int J Cardiol. 2009;136:4-16.
20. Musa-Veloso K, Binns MA, Kocenas AC, et al. Long-chain omega-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid dose-dependently reduce fasting serum triglycerides. Nutr Rev. 2010;68:155-167.
21. Sadovsky R, Kris-Etherton P. Prescription omega-3-acid ethyl esters for the treatment of very high triglycerides. Postgrad Med. 2009;121:145-153.
22. Raatz SK, Redmon JB, Wimmergren N, Donadio JV, Bibus DM. Enhanced absorption of n-3 fatty acids from emulsifi ed compared with encapsulated fi sh oil. J Am Diet Assoc. 2009;109:1076-1081.
23. Ryan AS, Keske MA, Hoffman JP, Nelson EB. Clinical overview of algal-docosahexaenoic acid: effects on triglyceride levels and other cardiovascular risk factors. Am J Ther. 2009;16:183-192.
24. Kris-Etherton PM, William SH, Appel LJ. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation. 2002;106:2747-2757. (Pubitemid 35364932)
25. Madsen T, Christensen JH, Schmidt EB. C-reactive protein and n-3 fatty acids in patients with a previous myocardial infarction: a placebo-controlled randomized study. Eur J Nutr. 2007;46:428-430. (Pubitemid 350276230)
26. Kannel WB, Vasan RS. Triglycerides as vascular risk factors: new epidemiologic insights. Curr Opin Cardiol. 2009;24:345-350.
27. European AIDS Clinical Society (EACS). Prevention and management of non-infectious co-morbidities in HIV. Version 4-5. 2009. www. europeanaidsclinicalsociety.org